8 news items
Kineta Provides Update On Its Ongoing Phase 1/2 VISTA-101 Clinical Trial And Corporate Activities; Received $500,000 Investment From An Existing Investor
KA
15 May 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
KA
15 May 24
Partial response
Why Ascent Solar Technologies Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
ACB
ACORQ
ADIL
10 Apr 24
. (NASDAQ:KA) dipped 14% to $0.3699. Kineta recently reported initial clinical response data at the AACR 2024 of its ongoing Phase 1/2 VISTA
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
ACB
ACRV
AMD
9 Apr 24
. (NASDAQ:KA) fell 17.1% to $0.4490. Kineta reported initial clinical response data at the AACR 2024 of its ongoing Phase 1/2 VISTA-101 clinical trial
Kineta Reports Initial Clinical Response Data At AACR 2024 Of Ongoing Phase 1/2 VISTA-101 Clinical Trial
KA
8 Apr 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
1qbojumd8dtcbsq4z369ob5ug8djs7kbcxvn13s46vdxlli5y
KA
8 Apr 24
Partial response
ptuavzxb32yivjto0sdam8ddwqs1
KA
21 Mar 24
Partial response
hvmzo424ube3p2vxwkxnycvvt9nc
KA
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
- Prev
- 1
- Next